Subtype
Bile Duct Neoplasm
CI-CAN-00000563Explore in graph →
Non-malignant224 active trials3 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000563Explore in graph →
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05930119 | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | completed | Phase 1 | 24 | HutchmedINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03003065 | Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers(PDT) | completed | Phase 2 | 10 | Chinese University of Hong KongOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04072445 | Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04034238 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03278106 | TAS-102 in Treating Advanced Biliary Tract Cancers | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02520141 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03473574 | Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients(IMMUCHEC) | completed | Phase 2 | 128 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02351765 | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers(ABC-08) | completed | Phase 1 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT01845337 | Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine(TOFFEE) | completed | Phase 2 | 59 | University of EdinburghOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy(EPIC-1511) | completed | Phase 3 | 480 | Centre Oscar LambretOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03895970 | Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors | completed | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02821754 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05028439 | RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma | completed | N/A | 70 | First People's Hospital of HangzhouOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04476082 | Nutrition in Gastrointestinal Tumors(NutriGIT) | completed | — | 66 | University Medicine GreifswaldOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT00286013 | Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma | completed | Phase 2 | 24 | University Hospital, GhentOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT03079427 | Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma | completed | Phase 2 | 101 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05266300 | Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. | completed | — | 722 | University of Southern DenmarkOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT03769753 | Trial of IRE in Cholangiocarcinoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05489692 | HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma | completed | — | 43 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT05464706 | Study on the Quality of Life (QoL) After Liver Surgery | completed | N/A | 60 | Humanitas Clinical and Research CenterOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02451553 | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | completed | Phase 1 | 41 | University of WashingtonOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05402618 | Minimally Invasive Versus Open Surgery for PHC | completed | — | 783 | Renyi QinOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04316078 | A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies | completed | N/A | 126 | Sheba Medical CenterOTHER_GOV | 1 | Apr 28, 2022 | clinicaltrials |
| NCT04611100 | Efficacy of Intraductal Radiofrequency Ablation in Combination With Metallic Biliary Stenting in Advanced Hilar Cholangiocarcinoma | completed | N/A | 70 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Mar 23, 2022 | clinicaltrials |
| NCT02591030 | Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours(AMEBICA) | completed | Phase 2 / Phase 3 | 191 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04847167 | Mechanistic Loop Resolution Strategy for Short-type Single Balloon Enteroscopy | completed | N/A | 23 | Ajou University School of MedicineOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03796819 | Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma(LND for ICC) | completed | N/A | 260 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT03111732 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2021 | clinicaltrials |
| NCT04937322 | Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry. | completed | — | 8 | Methodist Health SystemOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT03486678 | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | completed | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT02128282 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | completed | Phase 1 / Phase 2 | 127 | Senhwa Biosciences, Inc.INDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT03644173 | Personal Resilience Empowerment Program Study | completed | N/A | 37 | Hackensack Meridian HealthOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT02115542 | Single Agent Regorafenib in Refractory Advanced Biliary Cancers | completed | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT03041662 | Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)(PSC) | completed | — | 620 | Karolinska University HospitalOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04301999 | Clinical Effect and Safety of PDT and RFA for Unresectable EHCC | completed | N/A | 67 | First People's Hospital of HangzhouOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT02631590 | Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | completed | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04656249 | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer(LENABC) | completed | Phase 2 | 46 | Peking Union Medical College HospitalOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04642664 | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer(ACABC) | completed | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT03405909 | Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study(ESCULAP) | completed | — | 517 | University Hospital ErlangenOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT03338062 | A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy | completed | N/A | 15 | Indiana UniversityOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Sep 6, 2023source: clinicaltrials